Mineralys Therapeutics(US:MLYS) ZACKS·2025-09-09 17:01Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Mineralys Therapeutics, Inc. (MLYS) - MLYS currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Performance Metrics - MLYS shares have increased by 124.81% over the past week, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 1.17% [5] - Over the past month, MLYS's price change is 172.4%, while the industry only saw a 4.66% increase [5] - In the last three months, MLYS shares rose by 167.14%, and over the past year, they increased by 203.46%, compared to the S&P 500's gains of 8.64% and 21.49%, respectively [6] Trading Volume - MLYS has an average 20-day trading volume of 2,452,919 shares, which is considered a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, four earnings estimates for MLYS have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$3.31 to -$2.83 [9] - For the next fiscal year, three estimates have also moved upwards with no downward revisions [9] Conclusion - Given the strong performance metrics and positive earnings outlook, MLYS is positioned as a promising investment opportunity with a Momentum Score of A [11]